ANKRD30A抗体ANKRD30A一抗抗体Serologi
cally defined breast cancer antigen NY-BR-1 antibody抗体ANKRD30A Antibody抗体- ￥880 - 1320
- CUSABIO
- CN
- CSB-PA000876
- 2025年07月15日
- WB, IHC, ELISA; WB:1:500-1:2000, IHC:1:100-1:300, ELISA:1:5000
- Rabbit
- Human
企业认证
相关产品推荐更多 >
PQLC3抗体PQLC3兔多抗抗体PQ-loop repeat-containing protein 3抗体PQLC3 Antibody, Biotin conjugated抗体
￥880
MSN抗体MSN兔多抗抗体MS/LK fusion antibody抗体MSN Antibody, Biotin conjugated抗体
￥880
Bad抗体Bad兔多抗抗体/抗体Bad (Ab-155) Antibody抗体
￥2024
PHC1抗体PHC1兔多抗抗体Rae28 antibody抗体PHC1 Antibody, HRP conjugated抗体
￥880
MTOR抗体MTOR一抗抗体Serine/threonine-protein kinase mTOR antibody抗体MTOR Antibody抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Synthesized peptide derived from the C-terminal region of Human ANKRD30A.
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
/
- 标记物：
Non-conjugated
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q9BXX3
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
WB, IHC, ELISA; WB:1:500-1:2000, IHC:1:100-1:300, ELISA:1:5000
- 浓度：
>95%,The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- 靶点：
ANKRD30A
- 抗体英文名：
ANKRD30A Antibody
- 抗体名：
ANKRD30AAnkyrin repeat domain-containing protein 30A antibody;Serologically defined breast cancer antigen NY-BR-1 antibody
- 规格：
100μg/50μg
| 规格： | 100μg | 产品价格： | ￥1320.0 |
|---|---|---|---|
| 规格： | 50μg | 产品价格： | ￥880.0 |
保存缓冲液
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.功能
/风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Quantitative Angiogenesis in Breast Cancer
VIII-related antigen at high power over a defined field area. The generation of more sensitive and specific markers—in particular antibodies to CD34—together with the use of a Chalkley eyepiece graticule have improved the objectivity of the assessment
Potential Target Antigens for Immunotherapy Identified by Serological Expression Cloning (SEREX)
immunogenicity, identification of potential peptide epitopes for CD8 and CD4 T-cells, and evaluation in T-cell assays to demonstrate their potential use as vaccine targets. We recently identified a new breast cancer differentiation antigen
Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection
FDA-approved (1998) for metastatizing breast tumors; phase III for early breast cancer tumors.
技术资料暂无技术资料 索取技术资料
